Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RAMSEY, N.J. AND BOCA RATON, FLA., JAN. 05, 2026 (GLOBE NEWSWIRE) -- ADMA BIOLOGICS, INC. (NASDAQ: ADMA) (ADMA OR THE COMPANY), A U.S.-BASED, END-TO-END COMMERCIAL BIOPHARMACEUTICAL COMPANY DEDICATED TO MANUFACTURING, MARKETING, AND DEVELOPING SPECIALTY BIOLOGICS, TODAY ANNOUNCED THAT ADAM GROSSMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A PODIUM PRESENTATION AT THE J.P. MORGAN HEALTHCARE CONFERENCE ON MONDAY, JANUARY 12, 2026, AT 9:45 A.M. PT.

ADMA BIOLOGICS TO PRESENT AT THE J.P. MORGAN HEALTHCARE CONFERENCE ON JANUARY 12, 2026

3Q 2025 TOTAL REVENUE OF $134.2 MILLION, A 12% YOY INCREASE 3Q 2025 GAAP NET INCOME OF $36.4 MILLION, A 1% YOY INCREASE 3Q 2025 ADJUSTED EBITDA (1) OF $58.7 MILLION, A 29% YOY INCREASE 3Q 2025 ADJUSTED NET INCOME (2) OF $38.9 MILLION, AN 8% YOY INCREASE FDA LOT RELEASE OF FIRST YIELD-ENHANCED PRODUCTION BATCHES POSITIONS ADMA FOR MARGIN EXPANSION BEGINNING IN 4Q 2025 AND CONTINUING THROUGH 2026 POSITIVE, STATISTICALLY SIGNIFICANT REAL-WORLD HEALTH OUTCOMES DEMONSTRATED FOR ASCENIV RECORD ASCENIV DEMAND AND ANTICIPATED 2026 PAYER COVERAGE EXPANSION SUPPORT SUSTAINED AND ACCELERATING REVENUE GROWTH TRAJECTORY ADVANCING SG-001 PIPELINE PROGRAM AND CNPV VOUCHER APPLICATION SUBMITTED; STRENGTHEN LONG-TERM PIPELINE OUTLOOK ONGOING SHARE REPURCHASES AND STRENGTHENED CAPITAL STRUCTURE SUPPORT LONG-TERM STOCKHOLDER VALUE CREATION RAISING FY 2025 TOTAL REVENUE GUIDANCE TO $510 MILLION OR MORE AND FY 2026 TOTAL REVENUE GUIDANCE TO $630 MILLION OR MORE REAFFIRMING FY 2025 ADJUSTED EBITDA GUIDANCE OF $235 MILLION AND RAISING FY 2026 ADJUSTED EBITDA GUIDANCE TO $355 MILLION REVISING FY 2025 ADJUSTED NET INCOME GUIDANCE TO APPROXIMATELY $158 MILLION TO REFLECT A HIGHER EFFECTIVE TAX RATE AND RAISING FY 2026 ADJUSTED NET INCOME GUIDANCE TO MORE THAN $255 MILLION PROJECTING TOTAL ANNUAL REVENUE TO EXCEED $1.1 BILLION IN FY 2029 WITH ANTICIPATED OUTSIZED EARNINGS GROWTH AND OPERATIONAL MOMENTUM FROM CURRENT MARGIN LEVELS RAMSEY, N.J. AND BOCA RATON, FLA.

ADMA BIOLOGICS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ADMA BIOLOGICS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 5, 2025

2Q 2025 TOTAL REVENUE OF $122.0 MILLION, A 14% YOY INCREASE, AND A 29% YOY INCREASE EXCLUDING A PRIOR YEAR NON-RECURRING ITEM

ADMA BIOLOGICS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ADMA BIOLOGICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 6, 2025

1Q 2025 TOTAL REVENUE OF $114.8 MILLION (ADJUSTED TOTAL REVENUE ( 1 ) OF $118.6 MILLION), A 40% YOY INCREASE

ADMA BIOLOGICS ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ADMA BIOLOGICS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 7, 2025

APPROVAL SUPPORTS REVENUE GROWTH AND MARGIN EXPANSION OPPORTUNITY, AND SUBSTANTIALLY INCREASES PEAK PRODUCTION OUTPUT CAPACITY

ADMA BIOLOGICS ANNOUNCES U.S. FDA APPROVAL OF INNOVATIVE PRODUCTION YIELD ENHANCEMENT PROCESS

REITERATES STRATEGIC ADVANTAGE THROUGH FULLY U.S.-BASED MANUFACTURING OPERATIONS, COMMERCIALIZATION AND END-MARKET SALES, AND VERTICALLY INTEGRATED U.S.-BASED SUPPLY CHAIN REITERATES STRATEGIC ADVANTAGE THROUGH FULLY U.S.-BASED MANUFACTURING OPERATIONS, COMMERCIALIZATION AND END-MARKET SALES, AND VERTICALLY INTEGRATED U.S.-BASED SUPPLY CHAIN

ADMA BIOLOGICS STATEMENT ON TARIFFS

NEW YORK, NY / ACCESS NEWSWIRE / MARCH 5, 2025 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCED AN INVESTIGATION OF ADMA BIOLOGICS, INC. ("ADMA BIOLOGICS, INC.") (NASDAQ:ADMA) CONCERNING POSSIBLE VIOLATIONS OF FEDERAL SECURITIES LAWS. ADMA BIOLOGICS ANNOUNCED A DELAY IN FILING ITS FORM 10-K, CITING AN ONGOING AUDIT BY KPMG FOCUSED ON EVALUATING INTERNAL CONTROLS.

LOST MONEY ON ADMA BIOLOGICS, INC.(ADMA)? YOU MAY HAVE BEEN AFFECTED BY FRAUD- CONTACT LEVI & KORSINSKY

FY 2024 TOTAL REVENUE OF $426.5 MILLION, A 65% YOY INCREASE FY 2024 GAAP NET INCOME OF $197.7 MILLION, INCLUDING AN $84.3 MILLION VALUATION ALLOWANCE TAX BENEFIT FY 2024 ADJUSTED EBITDA (1) OF $164.6 MILLION, A 309% YOY INCREASE FY 2024 ADJUSTED NET INCOME ( 2 ) OF $119.2 MILLION, COMPARED TO $0.7 MILLION IN FY 2023, A 16,810% YOY INCREASE YE 2024 TOTAL CASH GREW TO MORE THAN $103 MILLION, INCLUDING $60 MILLION OF DEBT ORGANICALLY DISCHARGED DURING 2H 2024 HIGH-TITER PLASMA SUPPLY CONTRACTS EXPECTED TO PROVIDE FOUNDATION FOR DURABLE ASCENIV REVENUE GROWTH THROUGH LATE 2030S FDA APPROVAL OF YIELD ENHANCEMENT PRODUCTION PROCESS ANTICIPATED BY MID-2025 FY 2025 AND 2026 TOTAL REVENUE GUIDANCE INCREASED TO MORE THAN $490 MILLION AND $605 MILLION, RESPECTIVELY FY 2025 AND 2026 ADJUSTED NET INCOME GUIDANCE INCREASED TO MORE THAN $175 MILLION AND $235 MILLION, RESPECTIVELY FY 2025 AND 2026 ADJUSTED EBITDA GUIDANCE INCREASED TO MORE THAN $225 MILLION AND $305 MILLION, RESPECTIVELY ADMA ANTICIPATES GENERATING GREATER THAN $1 BILLION IN TOTAL ANNUAL REVENUE PRIOR TO 2030, MORE THAN DOUBLING THE CURRENT 2025 REVENUE FORECAST RAMSEY, N.J. AND BOCA RATON, FLA.

ADMA Biologics, Inc.

ADMA

Price

Financial Reports

No items found.

Press Releases

ADMA Biologics, Inc.

ADMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ADMA